NYSE:TARO (Israel) Also trade in: Germany

Taro Pharmaceutical Industries Ltd

$ 94.77 0.12 (0.13%)
On watch
Volume: 30,403 Avg Vol (1m): 71,800
Market Cap $: 3.74 Bil Enterprise Value $: 2.70 Bil
P/E (TTM): 12.17 P/B: 2.04
Earnings Power Value 127.72
Net Current Asset Value 31.58
Tangible Book 47.16
Projected FCF 123.6
Median P/S Value 78.23
Graham Number 91.44
Peter Lynch Value 0
DCF (FCF Based) 90.09
DCF (Earnings Based) 224.33
1Y (-%)

Financial Strength : 10/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
98.72% of 859 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
TARO: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.02, Med: 0.79, Max: 10000
Current: 10000
0.02
10000
Equity-to-Asset 0.89
Equity-to-Asset ranked higher than
92.64% of 788 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1.78, Med: 0.64, Min: -27.83
TARO: 0.89
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.17, Med: 0.54, Max: 0.92
Current: 0.89
0.17
0.92
Interest Coverage No Debt
Interest Coverage ranked lower than
81.02% of 648 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 2689668, Med: 86.08, Min: 0.01
TARO: No Debt
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 16.91, Med: 207.4, Max: 10000
Current: 10000
16.91
10000
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 12.30
DISTRESS
GREY
SAFE
Beneish M-Score -2.45
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 28.86%
WACC 7.11%

Profitability & Growth : 8/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 44.44
Operating Margin ranked higher than
98.00% of 801 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
TARO: 44.44
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: 14.17, Med: 47.38, Max: 64.63
Current: 44.44
14.17
64.63
Net Margin % 46.55
Net Margin ranked higher than
94.64% of 802 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
TARO: 46.55
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: 9.28, Med: 37.91, Max: 56.9
Current: 46.55
9.28
56.9
ROE % 14.25
ROE ranked higher than
63.46% of 832 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 316.96, Med: 5.94, Min: -3119.47
TARO: 14.25
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: 9.88, Med: 34.5, Max: 49.88
Current: 14.25
9.88
49.88
ROA % 12.95
ROA ranked higher than
76.23% of 871 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
TARO: 12.95
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: 6.38, Med: 24.38, Max: 32.05
Current: 12.95
6.38
32.05
ROC (Joel Greenblatt) % 82.16
ROC (Joel Greenblatt) ranked higher than
85.61% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
TARO: 82.16
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: 19.43, Med: 105.41, Max: 165.33
Current: 82.16
19.43
165.33
3-Year Total Revenue Growth Rate -8.50
3-Year Revenue Growth Rate ranked lower than
82.29% of 689 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 291.9, Med: 5.8, Min: -100
TARO: -6.5
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -6.8, Med: 13.1, Max: 34.7
Current: -6.5
-6.8
34.7
3-Year Total EBITDA Growth Rate -19.80
3-Year EBITDA Growth Rate ranked lower than
84.94% of 704 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 299.6, Med: 7.3, Min: -343.2
TARO: -18
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
N/A
3-Year EPS w/o NRI Growth Rate -22.50
3-Year EPS w/o NRI Growth Rate ranked lower than
85.07% of 663 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 385.8, Med: 8.9, Min: -403.2
TARO: -22.5
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 28.3, Max: 119
Current: -22.5
0
119

» TARO's 30-Y Financials

Financials (Next Earnings Date: 2019-08-09)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:TARO

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS : 325412    SIC : 2834
Compare BSP:HYPE3 SHSE:600566 SHSE:603858 SZSE:000999 TSE:4516 OHEL:ORNAV NYSE:AMRX SZSE:000423 BUD:RICHTER BOM:532321 NAS:HZNP SHSE:600277 XTER:EVT SHSE:600535 LIM:BAYERI1 TSE:4530 SZSE:300601 XCNQ:CURA NAS:TLRY JSE:APN
Traded in other countries TAL.Germany
Address 14 Hakitor Street, PO Box 10347, Haifa Bay, ISR, 2624761
Taro Pharmaceutical Industries Ltd produces, researches, develops and markets pharmaceutical products. Its primary focus includes semi-solids formulations, such as creams and ointments and other dosage forms such as liquids, capsules and tablets. It is engaged in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. It develops, manufactures and markets Rx and OTC pharmaceutical products primarily in the United States, Canada and Israel.

Ratios

Current vs industry vs history
PE Ratio (TTM) 12.17
PE Ratio ranked higher than
60.68% of 557 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1910, Med: 23.77, Min: 0.06
TARO: 12.17
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 3.13, Med: 10.75, Max: 21.8
Current: 12.17
3.13
21.8
Forward PE Ratio 8.61
Forward P/E ranked higher than
86.49% of 111 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 322.58, Med: 21.6, Min: 5.03
TARO: 8.61
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 12.17
PE without NRI ranked higher than
61.87% of 556 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 2125, Med: 24.2, Min: 0.06
TARO: 12.17
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 2.84, Med: 10.73, Max: 21.8
Current: 12.17
2.84
21.8
Price-to-Owner-Earnings 9.29
Price-to-Owner-Earnings ranked higher than
81.48% of 324 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 3160, Med: 31.95, Min: 0.17
TARO: 9.29
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 3.5, Med: 10.49, Max: 24.08
Current: 9.29
3.5
24.08
PB Ratio 2.04
PB Ratio ranked higher than
64.59% of 819 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 227.39, Med: 2.64, Min: 0.05
TARO: 2.04
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 1.18, Med: 2.26, Max: 6.4
Current: 2.04
1.18
6.4
PS Ratio 5.69
PS Ratio ranked lower than
73.03% of 775 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 9105.26, Med: 3.1, Min: 0.03
TARO: 5.69
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 1, Med: 4.62, Max: 9.63
Current: 5.69
1
9.63
Price-to-Free-Cash-Flow 11.40
Price-to-Free-Cash-Flow ranked higher than
81.54% of 298 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 3143.75, Med: 30.84, Min: 0.23
TARO: 11.4
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 5.93, Med: 12.09, Max: 27.73
Current: 11.4
5.93
27.73
Price-to-Operating-Cash-Flow 10.39
Price-to-Operating-Cash-Flow ranked higher than
74.74% of 392 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 14229.87, Med: 22, Min: 0.23
TARO: 10.39
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 5.68, Med: 11.01, Max: 25.85
Current: 10.39
5.68
25.85
EV-to-EBIT 9.45
EV-to-EBIT ranked higher than
85.14% of 572 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
TARO: 9.45
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: 4.3, Med: 7.8, Max: 37.5
Current: 9.45
4.3
37.5
EV-to-EBITDA 8.87
EV-to-EBITDA ranked higher than
80.74% of 597 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
TARO: 8.87
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: 4, Med: 7.2, Max: 37.5
Current: 8.87
4
37.5
EV-to-Revenue 4.08
EV-to-Revenue ranked lower than
58.11% of 795 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
TARO: 4.08
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 1.2, Med: 3.4, Max: 8.5
Current: 4.08
1.2
8.5
PEG Ratio 5.61
PEG Ratio ranked lower than
89.59% of 317 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1472, Med: 1.93, Min: 0.07
TARO: 5.61
Ranked among companies with meaningful PEG Ratio only.
PEG Ratio range over the past 10 years
Min: 0.13, Med: 0.31, Max: 13.75
Current: 5.61
0.13
13.75
Shiller PE Ratio 13.05
Shiller PE Ratio ranked higher than
86.90% of 252 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1460.4, Med: 32.75, Min: 0.08
TARO: 13.05
Ranked among companies with meaningful Shiller PE Ratio only.
Shiller PE Ratio range over the past 10 years
Min: 10.6, Med: 19.16, Max: 58.09
Current: 13.05
10.6
58.09
Current Ratio 6.69
Current Ratio ranked higher than
89.82% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
TARO: 6.69
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.51, Med: 2.54, Max: 9.56
Current: 6.69
0.51
9.56
Quick Ratio 6.01
Quick Ratio ranked higher than
89.47% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
TARO: 6.01
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.29, Med: 1.85, Max: 8.85
Current: 6.01
0.29
8.85
Days Inventory 244.13
Days Inventory ranked lower than
89.27% of 755 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
TARO: 244.13
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 163.69, Med: 228.1, Max: 274.97
Current: 244.13
163.69
274.97
Days Sales Outstanding 122.80
Days Sales Outstanding ranked lower than
72.47% of 770 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 864.61, Med: 81.76, Min: 0.1
TARO: 122.8
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 63.21, Med: 76.77, Max: 122.8
Current: 122.8
63.21
122.8
Days Payable 53.90
Days Payable ranked lower than
72.82% of 758 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
TARO: 53.9
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 28.75, Med: 44.81, Max: 69.43
Current: 53.9
28.75
69.43

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate 2.70
3-Year Share Buyback Rate ranked higher than
97.20% of 571 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 100, Med: -5.3, Min: -815
TARO: 2.7
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -18.4, Med: -3.2, Max: 2.7
Current: 2.7
-18.4
2.7

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 2.03
Price-to-Tangible-Book ranked higher than
72.36% of 749 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 972.22, Med: 3.33, Min: 0.05
TARO: 2.03
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 0.89, Med: 2.3, Max: 21.79
Current: 2.03
0.89
21.79
Price-to-Projected-FCF 0.78
Price-to-Intrinsic-Value-Projected-FCF ranked higher than
87.97% of 374 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 209, Med: 2.11, Min: 0.05
TARO: 0.78
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.68, Med: 1.68, Max: 23.54
Current: 0.78
0.68
23.54
Price-to-DCF (Earnings Based) 0.43
Price-to-Intrinsic-Value-DCF (Earnings Based) ranked lower than
100.00% of 110 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 27.76, Med: 1.36, Min: 0.14
TARO: 0.43
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
Price-to-Intrinsic-Value-DCF (Earnings Based) range over the past 10 years
Min: 0.38, Med: 1.07, Max: 6.94
Current: 0.43
0.38
6.94
Price-to-Median-PS-Value 1.23
Price-to-Median-PS-Value ranked lower than
78.73% of 743 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 238.36, Med: 0.94, Min: 0.01
TARO: 1.23
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.08, Med: 0.65, Max: 1.92
Current: 1.23
0.08
1.92
Price-to-Graham-Number 1.05
Price-to-Graham-Number ranked higher than
69.02% of 481 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 36.65, Med: 1.81, Min: 0.02
TARO: 1.05
Ranked among companies with meaningful Price-to-Graham-Number only.
Price-to-Graham-Number range over the past 10 years
Min: 0.41, Med: 1.24, Max: 11.74
Current: 1.05
0.41
11.74
Earnings Yield (Joel Greenblatt) % 10.58
Earnings Yield (Greenblatt) ranked higher than
90.20% of 867 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
TARO: 10.58
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: 2.7, Med: 12.9, Max: 23
Current: 10.58
2.7
23
Forward Rate of Return (Yacktman) % 1.59
Forward Rate of Return ranked higher than
59.86% of 421 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 559.55, Med: 8.96, Min: -1635.32
TARO: 1.59
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: -21.4, Med: 5.4, Max: 27.8
Current: 1.59
-21.4
27.8

More Statistics

Revenue (TTM) (Mil) $ 665.19
EPS (TTM) $ 7.88
Beta 0.86
Volatility % 28.47
52-Week Range $ 76.93 - 121.23
Shares Outstanding (Mil) 39.02

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy Y
Higher Gross Margin yoy N
Higher Asset Turnover yoy N